RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Detail |
|
Starting dose
|
100 mg twice daily — for patients currently tolerating a moderate-to-high dose ACE inhibitor (e.g., enalapril ≥ 10 mg BD or equivalent) or ARB (e.g., valsartan ≥ 160 mg daily or equivalent)
|
|
50 mg twice daily — for patients: (a) not currently on an ACE inhibitor or ARB, (b) previously on low-dose ACE inhibitor or ARB, © with systolic BP 100–110 mmHg, (d) with moderate renal impairment (eGFR 30–60 mL/min/1.73 m²), or (e) with moderate hepatic impairment (Child-Pugh B)
|
|
|
Titration
|
Double the dose every 2–4 weeks as tolerated (50 mg BD → 100 mg BD → 200 mg BD); titrate only if systolic BP ≥ 95 mmHg, no symptomatic hypotension, no hyperkalaemia (K⁺ < 5.4 mEq/L), and no significant worsening of renal function |
|
Usual maintenance dose
|
200 mg twice daily (target dose) |
|
Maximum dose
|
200 mg twice daily |
|
Key clinical notes
|
• Mandatory 36-hour washout from any ACE inhibitor before initiating sacubitril/valsartan — concurrent or closely timed use with ACE inhibitors markedly increases risk of angioedema • No washout required when switching from an ARB • Replaces ACE inhibitor/ARB in guideline-directed medical therapy (GDMT) for HFrEF; should be used in conjunction with a beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor as part of the four-pillar HF therapy • Based on the PARADIGM-HF trial, sacubitril/valsartan reduced cardiovascular death and heart failure hospitalisation by 20% compared with enalapril • Do not initiate in acutely decompensated heart failure requiring intravenous therapy; stabilise the patient first and initiate during the index hospitalisation before discharge or within the early post-discharge period • If a dose is missed, take the next dose at the scheduled time; do not double dose • Sacubitril inhibits neprilysin, leading to increased levels of natriuretic peptides (BNP); therefore, BNP cannot be used as a marker for monitoring HF status during treatment — use NT-proBNP instead, which is not a neprilysin substrate • Hypotension is the most common reason for dose reduction or discontinuation; optimise diuretic dosing, avoid unnecessary vasodilators, and consider reducing concomitant antihypertensives before down-titrating ARNI
|
| eGFR (mL/min/1.73 m²) | Recommendation |
|
≥ 60
|
No dose adjustment required; standard dosing |
|
30–59
|
Start at 50 mg twice daily; titrate cautiously based on tolerability; monitor renal function and potassium within 1–2 weeks |
|
< 30 (not on dialysis)
|
Limited data; use with extreme caution under specialist supervision; start at 50 mg twice daily if initiated; close monitoring of renal function, potassium, and blood pressure essential |
|
End-stage renal disease / Haemodialysis
|
Not recommended; no adequate data available |
| Child-Pugh Class | Recommendation |
|
A (Mild)
|
No dose adjustment required |
|
B (Moderate)
|
Initiate at 50 mg twice daily; titrate cautiously with close monitoring of liver function, blood pressure, and tolerability; area under curve of valsartan approximately doubled |
|
C (Severe)
|
Not recommended; no safety or efficacy data available; avoid use |
| Parameter | Detail |
|
Overall safety
|
Contraindicated — Risk Category D; acts on the RAAS (valsartan component) and is associated with fetal toxicity including renal dysgenesis, oligohydramnios, skull ossification defects, pulmonary hypoplasia, and neonatal death when used in the second and third trimesters |
|
First trimester
|
Should be avoided; discontinue immediately upon confirmation of pregnancy and switch to a safer alternative |
|
Preferred alternatives in Indian obstetric practice
|
Methyldopa (first line for chronic hypertension/heart failure in pregnancy); labetalol; hydralazine with nitrate for acute heart failure management in pregnancy |
|
When it may be used
|
Should not be used at any stage of pregnancy |
|
Monitoring if inadvertently exposed
|
Serial ultrasonography for amniotic fluid volume, fetal renal function, limb contractures, and skull ossification; neonatal assessment for hypotension, hyperkalaemia, oliguria, and renal failure |
| Parameter | Detail |
|
Compatibility with breastfeeding
|
Not recommended; unknown whether sacubitril, its active metabolite LBQ657, or valsartan is excreted in human breast milk (demonstrated in animal milk) |
|
Expected drug levels in milk
|
Unknown in humans |
|
Preferred alternatives
|
For heart failure management during lactation — hydralazine plus nitrate combination, or beta-blockers (carvedilol, metoprolol succinate); consult cardiologist and neonatologist |
|
Monitoring in infant
|
If exposure occurs, monitor infant for hypotension (lethargy, poor feeding, excessive sleepiness), decreased urine output, and poor weight gain |
| Interacting Drug/Class | Effect / Mechanism | Action |
|
ACE inhibitors (e.g., enalapril, ramipril, lisinopril)
|
Sacubitril inhibits neprilysin which degrades bradykinin; ACE inhibitors also increase bradykinin → combined use dramatically increases angioedema risk |
Absolutely contraindicated concurrently; mandatory 36-hour washout in both directions
|
|
Aliskiren (in diabetic or renally impaired patients)
|
Triple RAAS blockade → markedly increased risk of hyperkalaemia, hypotension, and renal failure | Contraindicated in patients with diabetes or eGFR < 60; avoid combination in all patients if possible |
|
Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene)
|
Additive hyperkalaemia risk (RAAS blockade by both ARNI and MRA) | When MRA is part of GDMT, combination is acceptable but requires potassium monitoring within 1 week and periodically thereafter; hold if K⁺ > 5.4 mEq/L |
|
Lithium
|
ARBs reduce renal lithium clearance → elevated serum lithium and toxicity risk | Monitor lithium levels closely if combination is unavoidable; consider alternative mood stabiliser or alternative antihypertensive |
|
Potassium supplements
|
Additive hyperkalaemia | Avoid unless documented hypokalaemia; monitor K⁺ closely |
| Interacting Drug/Class | Effect | Action |
|
NSAIDs (including COX-2 inhibitors, commonly used in Indian practice for musculoskeletal complaints)
|
Attenuation of antihypertensive effect; increased risk of acute kidney injury and hyperkalaemia, especially in volume-depleted or elderly patients | Avoid prolonged concurrent use; if short-term NSAID is required, monitor BP, renal function, and potassium |
|
Thiazide or loop diuretics
|
Enhanced hypotensive effect; risk of volume depletion and pre-renal azotaemia | Optimise diuretic dose before initiating ARNI; reduce diuretic if symptomatic hypotension occurs; this is not a reason to withhold ARNI |
|
SGLT2 inhibitors (dapagliflozin, empagliflozin)
|
Additive blood pressure lowering and natriuresis; combination is part of recommended GDMT | Monitor BP and volume status; slight increase in risk of hypotension and dehydration; generally well tolerated |
|
Trimethoprim / co-trimoxazole
|
Trimethoprim acts as potassium-sparing diuretic → additive hyperkalaemia risk | Check serum potassium during concurrent use, particularly in elderly or renally impaired patients |
|
Statins (atorvastatin specifically)
|
Sacubitril may increase AUC of atorvastatin by up to 1.3-fold via OATP1B1/1B3 inhibition | Usually clinically insignificant; no routine dose adjustment needed; be aware if high-dose statin adverse effects emerge |
|
Sildenafil and other PDE5 inhibitors
|
Additive hypotensive effect | Use with caution; advise patients regarding positional hypotension; relevant in patients using PDE5 inhibitors for pulmonary hypertension as a comorbidity |
|
Metformin
|
Sacubitril may increase levels of metformin via inhibition of OAT3 transporter | Monitor for metformin-related gastrointestinal adverse effects; clinical significance is minor at usual metformin doses |
| Timing | Parameters |
|
Baseline (before initiation)
|
Blood pressure (supine and standing if possible), serum creatinine, eGFR, serum potassium, sodium, liver function tests, NT-proBNP (not BNP — see clinical notes), LVEF documentation, NYHA functional class, volume status assessment |
|
1–2 weeks after initiation or each dose change
|
Blood pressure (including orthostatic assessment), serum creatinine, eGFR, serum potassium |
|
Long-term (every 3–6 months for stable patients)
|
Blood pressure, renal function (creatinine, eGFR), serum potassium, sodium, NT-proBNP, NYHA class reassessment, LVEF (echocardiography at 3–6 months and then as clinically indicated) |
|
Situational
|
Recheck renal function and potassium during intercurrent illness (dehydration, vomiting, diarrhoea, fever), addition of interacting drugs (NSAID, MRA, diuretic dose change), or symptoms of hypotension; monitor for angioedema signs at every visit |
| Strength | Approximate Price per Tablet (INR) |
| 50 mg | ₹25–60 (generic) to ₹70–90 (originator) |
| 100 mg | ₹45–100 (generic) to ₹110–150 (originator) |
| 200 mg | ₹80–160 (generic) to ₹180–220 (originator) |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.